Predictive Oncology (POAI) AI Stock Analysis

• Market Cap: $8.04M
• Dividend Yield: N/A
• Average Volume (3M): 190.38K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.29
• Revenue Growth: -31.31%
• EPS Growth: 49.27%
• Country: US
• Employees: 23
• Sector: Healthcare
• Sector Strength: 48
• Industry: Medical - Instruments & Supplies
• EPS (TTM): -0.34
• Shares Outstanding: 8,931,621
• 10 Day Avg. Volume: 107,196
• 30 Day Avg. Volume: 190,383
• PEG Ratio: -0.02
• Price to Book (P/B): 1.03
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.74
• Enterprise Value/Market Cap: 0.06
• Enterprise Value/Revenue: 0.09
• Enterprise Value/Gross Profit: 1.05
• Enterprise Value/Ebitda: -0.01
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 41 Neutral
• Price Target: $1.00 ▲(14.94%Upside)

The overall stock score is heavily impacted by poor financial performance and valuation metrics. The technical analysis also indicates bearish momentum. Regulatory challenges and the potential for Nasdaq delisting exacerbate the company's risk profile.

Positive Factors

Technology

The proprietary AI platform PEDAL has demonstrated the potential to identify biomarkers in cancer patients, making it an attractive licensing target.

Negative Factors

Financial Performance

Predictive Oncology reported lower than expected revenue for 3Q24, indicating potential financial challenges.

Strategic Uncertainty

The company is undergoing a strategic review, which includes evaluating alternatives like a sale of the company or its assets, creating uncertainty.

Predictive Oncology Business Overview & Revenue Model

Company Description

Predictive Oncology Inc., a knowledge-driven company, focuses on developing personalized cancer therapies using artificial intelligence (AI) primarily in the United States. The company operates in four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment offers clinical testing services comprising tumor drug response testing and genomic profiling tests; and contract research services through patient-centric drug discovery using active learning technology for discovery, clinical and translational research, clinical trials, and diagnostic development and validation. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using High-Throughput Self-Interaction Chromatography, a self-contained, automated system that conducts high-throughput, self-interaction chromatography screens using additives and excipients that are included in protein formulations for soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates staff exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. It also offers research and development services; and media that help cancer cells grow outside the patient's body and retain their DNA/RNA and proteomic signatures. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is based in Eagan, Minnesota.

How the Company Makes Money

Predictive Oncology makes money through a diversified revenue model centered around its advanced biotechnology offerings. The company generates income primarily by providing its proprietary AI-driven platforms to healthcare institutions and pharmaceutical companies. These platforms facilitate drug discovery and optimize treatment plans by analyzing vast amounts of genomic and clinical data. Additionally, Predictive Oncology engages in strategic partnerships and collaborations with leading biotech and pharmaceutical firms, which further contribute to its revenue streams. The company's business model is bolstered by licensing agreements and service contracts, allowing access to its expansive database and predictive analytics tools. These partnerships and agreements are crucial in driving the company's growth and expanding its market reach.

Predictive Oncology Financial Statement Overview

Summary

Predictive Oncology faces significant financial challenges with declining revenues, negative profit margins, and deteriorating liquidity and solvency metrics. The company must address operational inefficiencies and stabilize its financial position.

Income Statement

The company shows a declining revenue trend with a negative revenue growth rate over the years. Gross profit margin has decreased from 64.7% in 2023 to 49.1% in 2024. The net profit margin is severely low due to net losses. EBIT and EBITDA margins are negative, indicating operational inefficiencies.

Balance Sheet

The balance sheet reveals financial instability with a negative stockholders' equity in 2024, indicating potential solvency issues. Debt-to-equity ratio is not applicable due to negative equity. The equity ratio is negative, reflecting a concerning capital structure.

Cash Flow

Operating cash flows remain negative, highlighting ongoing liquidity challenges. Free cash flow is also negative, but there is a slight improvement in free cash flow growth rate from 2023 to 2024. The operating cash flow to net income ratio is negative, indicating inefficiencies in converting income to cash.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
1.35M	1.62M	1.78M	1.51M	1.42M	1.25M
	Gross Profit
496.51K	797.68K	1.15M	1.00M	933.66K	805.08K
	EBIT
-9.91M	-10.94M	-14.08M	-15.27M	-13.47M	-666.27K
	EBITDA
-9.17M	-10.16M	-13.18M	-13.95M	-12.13M	-11.46M
	Net Income Common Stockholders
-8.45M	-12.20M	-13.98M	-36.21M	-19.66M	-37.70M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
3.09M	734.67K	8.73M	22.07M	28.20M	678.33K
	Total Assets
5.87M	4.97M	14.42M	25.73M	43.77M	13.06M
	Total Debt
1.92M	2.13M	2.86M	180.32K	879.33K	5.87M
	Net Debt
-1.17M	1.40M	-5.87M	-21.89M	-27.32M	5.20M
	Total Liabilities
6.01M	5.18M	6.15M	3.97M	3.51M	10.42M
	Stockholders Equity
-145.80K	-202.61K	8.27M	21.77M	40.27M	2.64M
Cash Flow		Free Cash Flow
-8.55M	-10.98M	-13.49M	-12.85M	-13.17M	-12.62M
	Operating Cash Flow
-8.54M	-10.97M	-13.19M	-12.37M	-12.21M	-12.26M
	Investing Cash Flow
618.52K	-9.51K	-302.37K	-475.70K	-10.61M	-167.46K
	Financing Cash Flow
6.55M	3.94M	148.90K	6.72M	50.34M	12.95M

Predictive Oncology Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.87
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For POAI, the sentiment is Negative. The current price of 0.87 is below the 20-day moving average (MA) of 0.94, below the 50-day MA of 1.00, and below the 200-day MA of 1.02, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 37.87 is Neutral, neither overbought nor oversold. The STOCH value of 11.11 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for POAI.

Predictive Oncology Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	53 Neutral	$5.24B	3.32	-44.36%	6.63%	16.78%	-0.12%
HBIO	51 Neutral	$21.57M	―	-138.80%	―	-14.41%	-549.88%
NXGL	48 Neutral	$24.68M	―	-62.82%	―	115.94%	17.42%
RVP	46 Neutral	$19.79M	―	-25.89%	―	-16.05%	-195.28%
EKSO	44 Neutral	$8.62M	―	-80.71%	―	-2.06%	49.73%
POAI	41 Neutral	$8.04M	―	-504.16%	―	-31.31%	49.27%
STSS		$5.54M	―	-75.14%	―	―	―

Predictive Oncology Corporate Events

Predictive Oncology Faces Nasdaq Delisting Notice

On June 9, 2025, Predictive Oncology Inc. received a notice from Nasdaq indicating its failure to meet the minimum stockholders’ equity requirement, leading to a potential delisting from the Nasdaq Capital Market. The company has requested a hearing to appeal this decision, which temporarily halts the delisting process, but there is no guarantee of a favorable outcome. Predictive Oncology is exploring options to regain compliance with Nasdaq’s listing requirements.

The most recent analyst rating on (POAI) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Predictive Oncology stock, see the POAI Stock Forecast page.

Predictive Oncology Ends Merger Talks with Renovaro

Predictive Oncology Inc. announced that it has discontinued discussions with Renovaro Inc. regarding a proposed merger, clarifying that no binding agreement was ever reached despite contrary claims by Renovaro. The letter of intent for the merger, initially signed on January 1, 2025, and extended on February 28, 2025, expired on March 31, 2025, leaving Predictive Oncology with no further obligations to Renovaro. The company remains focused on advancing its core business in AI-driven drug discovery and development.